Welcome to our dedicated page for Crown Resv Acquisition I SEC filings (Ticker: CRAC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Crown Resv Acquisition I's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Crown Resv Acquisition I's regulatory disclosures and financial reporting.
Crown Reserve Acquisition Corp. I entered into a Business Combination Agreement to domesticate to Delaware and merge its Merger Sub into Carvix, Inc., with Carvix surviving as a wholly owned subsidiary. At the Effective Time, Carvix shares will be cancelled in exchange for 50,000,001 Company shares in the aggregate and a contingent earnout of up to 50,000,100 additional shares tied to four-year EBITDA and revenue targets. Earnout mechanics split the aggregate Company Earnout Shares equally between an EBITDA component and a revenue component, with specified annual targets and catch-up/true-up features. The Sponsor may earn up to 3,000,000 Sponsor Earnout Shares in aggregate over three years. Closing is subject to customary conditions, including stockholder approvals, Domestication, SEC effectiveness of a Form S-4, Nasdaq listing approval, satisfaction of a Minimum Cash Amount, and other regulatory and closing conditions. The agreement includes customary representations, covenants, a Stockholder Support Agreement, a SPAC Founders Stock Letter and a form Investor Rights Agreement to be entered at Closing.
Crown Reserve Acquisition Corp. I entered a Business Combination Agreement with Carvix, Inc., under which Crown Reserve will domesticate from Cayman to Delaware and then merge a subsidiary into Carvix, leaving Carvix as a wholly owned subsidiary.
Carvix stockholders will receive an aggregate 50,000,001 shares of the post-combination company at closing, plus the right to earn up to an additional 50,000,100 shares over four fiscal years beginning January 1, 2027, based on EBITDA and revenue performance targets. The sponsor may also earn up to 3,000,000 shares over the first three years if specified milestones are met. Closing depends on stockholder approvals, SEC effectiveness of an S-4 registration statement, Nasdaq listing approval, antitrust clearance if required, minimum cash conditions and other customary requirements, with a potential outside date of September 30, 2026.
Crown Reserve Acquisition Corp. I announced a definitive Business Combination Agreement with Carvix, Inc., a technology-driven automotive platform, valuing Carvix at an implied enterprise value of $1.0 billion. A Crown Reserve subsidiary will merge into Carvix, which will become a wholly owned operating subsidiary.
Before closing, Crown Reserve plans to domesticate from the Cayman Islands to Delaware and remain the publicly traded parent, with the combined company’s shares expected to trade on Nasdaq. Closing is subject to shareholder and stockholder approvals, effectiveness of a Form S-4 registration statement, Nasdaq listing approval, a minimum cash condition, and no material adverse effect. The Business Combination Agreement can be terminated by either party if closing has not occurred by September 30, 2026.
Crown Reserve Acquisition Corp. I files its annual report outlining its SPAC structure and capital position. The company raised $172,500,000 in its IPO of 17,250,000 units at $10.00 per unit, each including one Class A share, half a warrant and one right. As of December 31, 2025, the Trust Account held $173,403,838, reflecting $903,838 of dividends. The SPAC has 12 months from its IPO closing, extendable to 15 months upon signing a business combination agreement, to complete an initial business combination or redeem public shares for cash. There were 17,250,000 Class A and 4,312,500 Class B ordinary shares outstanding, and 17,250,000 rights that would convert into 3,450,000 Class A shares upon a successful deal. The filing details redemption mechanics, sponsor founder shares, private placement units, warrant and right terms, and extensive risk factors related to completing a business combination and potential Investment Company Act issues.
Crown Reserve Acquisition Corp. I had a significant ownership disclosure as of December 31, 2025. Investment firm Magnetar Financial LLC and related entities reported beneficial ownership of 1,485,000 Class A ordinary shares, representing about 8.60% of the company’s outstanding Class A shares.
The shares are held across several Magnetar-managed funds, including Constellation Master Fund, Lake Credit Fund, Structured Credit Fund, Xing He Master Fund, Alpha Star Fund, Purpose Alternative Credit Fund - T, and Waterfront Series A. Based on the issuer’s report, there were approximately 17,250,000 Class A shares outstanding at that time.
Crown Reserve Acquisition Corp. I received an amended ownership report on its Class A common stock from a group of Harraden Circle investment entities and Frederick V. Fortmiller, Jr. The filing states that, as of 12/31/2025, the reporting persons beneficially own 0 shares, or 0% of the class.
The amendment is described as an exit filing, meaning this investor group previously held more than five percent of the outstanding Class A shares but no longer does so. The report also certifies that the securities referenced were not acquired or held for the purpose of changing or influencing control of the company.
Barclays PLC has disclosed a significant ownership position in Crown Reserve Acquisiti-CL A common stock. As of the event date of 12/31/2025, Barclays reports beneficial ownership of 1,125,750 common shares, representing 6.52% of the outstanding class.
Barclays reports sole voting and sole dispositive power over all of these shares, with no shared voting or dispositive authority. The firm states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Feis Equities LLC and Lawrence M. Feis filed an amended Schedule 13G reporting a passive ownership stake in Crown Reserve Acquisition Corp. I. They report beneficial ownership of 633,570 Class A ordinary shares, which represents 3.67% of the outstanding Class A shares. This percentage is based on 17,250,000 Class A ordinary shares outstanding as of November 14, 2025, as reported by the company.
Both Feis Equities LLC, an Illinois limited liability company, and Lawrence M. Feis, an individual U.S. citizen, report sole voting and sole dispositive power over the 633,570 shares, with no shared power. They also certify that the securities were not acquired and are not held for the purpose of changing or influencing control of Crown Reserve Acquisition Corp. I, indicating a passive investment position below the 5% ownership threshold.